CombiGene’s business concept is to develop effective gene therapies for treatment of difficult-to-treat diseases for which adequate treatment methods are currently lacking. The company intends to take its candidate drugs through the phases of preclinical development and initial clinical studies under its own management, and subsequently continue development and commercialization under its own management or in collaboration with other partners. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace Nasdaq First North and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se . For further information, please visit www.combigene.com. CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme
Looking for a particular CombiGene employee's phone or email?
CombiGene Questions
The CombiGene annual revenue was $1 million in 2026.
Birgitta Ståhl is the Senior Director In-licensing of CombiGene.
1 people are employed at CombiGene.
CombiGene is based in Lund, Skane.
The NAICS codes for CombiGene are [541, 54, 541713, 54171, 5417].
The SIC codes for CombiGene are [873, 87].
Top CombiGene Employees
-
Birgitta Ståhl
Senior Director In-licensing at CombiGene
Stockholm County, Sweden2
Related Companies
